This review discusses the available evidence concerning antiplatelet therapy in patients with CVD, with a focus on the role of clopidogrel.

Clopidogrel is an antiplatelet agent belonging to the thienopyridine family, that blocks the P2Y12 receptor on the platelet surface, inhibiting the ADP-induced ...

27 сент. 2024 г. · In conclusion, the results of our experiment demonstrated that aspirin and clopidogrel exhibited comparable efficacy in preventing ischemia in ...

27 мар. 2020 г. · This review discusses the available evidence concerning antiplatelet therapy in patients with CVD, with a focus on the role of clopidogrel.

Conclusions: Patients with CAD use clopidogrel could further reduce the risk of MACCE, MI, stroke, and BARC major bleeding, compared with the use of aspirin.

7 нояб. 2022 г. · The HOST-EXAM Extended study supports clopidogrel as the preferable antiplatelet agent prescribed for secondary prevention of coronary artery disease.

This study demonstrated that hypomethylation of CYP2C19 and miRNA-26a upregulation increased the risk of clopidogrel resistance in post-PCI patients.

Aspirin and clopidogrel resistance are emerging clinical entities with potentially severe consequences such as recurrent myocardial infarction, stroke, or ...

Our study demonstrates the benefit of adding clopidogrel to the regimen of treatment for patients with acute coronary syndromes without ST-segment elevation ...

The present study is aimed to assess the association between CYP2C19 metabolization status, clopidogrel resistance by PFT based on platelet reactivity units ( ...